Disclaimer: This is an early beta prototype. If you find any error, with data or functionality, please let us know via this page.
Registration date period
Results ordered by trial registration date, descending.
  1. PERINEURAL LOCAL ANAESTHETIC CATHETER AFTER MAJOR LOWER LIMB AMPUTATION TRIAL

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Unknown
    Source name:
    EU Clinical Trials Register

    The principal research question is whether it is feasible to run a pragmatic randomised controlled trial to investigate the effect of a PNC use plus usual care compared to usual care alone on...

    Conditions:
    • Analgesia for lower limb amputation for peripheral vascular disease (PVD)
    Interventions:
    • Chirocaine
  2. ANTLER, ANTidepressants to prevent reLapse in dEpRession

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Unknown
    Source name:
    EU Clinical Trials Register

    To estimate the effectiveness and cost-effectiveness of antidepressant medication in preventing relapse in UK primary care in people who have had two or more episodes of depression (including the...

    Conditions:
    • depression
    Interventions:
    • Mirtazapine Hexal
    • Sertralin Hexal
    • Citalopram Hexal
    • Fluoxetin EG
  3. Study of RA101495 in Paroxysmal Nocturnal Haemoglobinuria (PNH)

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Unknown
    Source name:
    EU Clinical Trials Register

    • To assess the safety and tolerability of RA101495 in subjects with PNH • To assess preliminary efficacy of RA101495 in subjects with PNH • To assess PK and PD of RA101495 in subjects with PNH

    Conditions:
    • Paroxysmal Nocturnal Haemoglobinuria (PNH)
    Interventions:
    • RA101495
  4. Filgotinib in Combination With Conventional Anti-rheumatic Drugs in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD treatment

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Unknown
    Source name:
    EU Clinical Trials Register

    The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the proportion of...

    Conditions:
    • Moderately to severely active rheumatoid arthritis
    Interventions:
    • Filgotinib
  5. Extension Study of RA101495 in Paroxysmal Nocturnal Haemoglobinuria (PNH)

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Unknown
    Source name:
    EU Clinical Trials Register

    • To provide access to RA101495 for subjects with PNH who have who have completed a Ra Pharmaceuticals sponsored study, have demonstrated clinical benefit, and who wish to continue receiving RA101495...

    Conditions:
    • Paroxysmal Nocturnal Haemoglobinuria (PNH)
    Interventions:
    • RA101495
  6. A study to assess a new treatment in patients with moderately to Severely active Ulcerative Colitis Estudio para evaluar un nuevo tratamiento en pacientes con Colitis Ulcerosa de actividad moderada a intensa

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Unknown
    Source name:
    EU Clinical Trials Register

    The primary objective of Cohort A Induction Study is: • To evaluate the efficacy of filgotinib as compared to placebo in establishing endoscopy/bleeding/stool (EBS) remission at Week 10 The primary...

    Conditions:
    • Moderately to Severely Active Ulcerative Colitis (UC)
    • Colitis Ulcerosa de actividad moderada a intensa (CU)
    Interventions:
    • Filgotinib
  7. A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with active ulcerative colitis

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Unknown
    Source name:
    EU Clinical Trials Register

    To investigate the safety and tolerability of 60 mg twice daily doses of GSK2982772 in subjects with moderate to severe ulcerative colitis.

    Conditions:
    • Active Ulcerative Colitis
    Interventions:
    • GSK2982772